Antiviral Generic Medicines
A Contract Award Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (‘NSS’)
- Source
- OJEU
- Type
- Framework (Supply)
- Duration
- 14 month (est.)
- Value
- £1M
- Sector
- HEALTH
- Published
- 02 Feb 2021
- Delivery
- To 04 Apr 2022 (est.)
- Deadline
- n/a
Concepts
Location
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014
2 buyers
- NHS National Services Scotland NSS Edinburgh
7 suppliers
- DR Reddys Laboratories Beverley
- Fresenius Kabi Runcorn
- Glenmark Pharmaceuticals Europe Watford
- Lupin Europe Knutsford
- Mylan Hatfield
- Roche Products Welwyn Garden City
- Teva Castleford
Description
Supply of antiviral generic medicines to NHS Scotland.
Lot Division
1 | Antiviral Generic Medicines Supply of a range of antiviral generic medicines used to treat conditions such as HIV, Hepatitis B, Hepatitis C and Influenza to NHS Scotland. The authority has awarded this Lot as a single supplier framework per line to seven (7) framework participants. |
2 | Emtricitabine/Tenofovir Disoproxil Supply of emtricitabine/tenofovir disoproxil to NHS Scotland. The authority has awarded this framework as a ranked multi-supplier framework to a four (4) framework participants. |
Award Detail
1 | DR Reddys Laboratories (Beverley)
|
2 | Fresenius Kabi (Runcorn)
|
3 | Glenmark Pharmaceuticals Europe (Watford)
|
4 | Lupin Europe (Knutsford)
|
5 | Mylan (Hatfield)
|
6 | Roche Products (Welwyn Garden City)
|
7 | DR Reddys Laboratories (Beverley)
|
8 | Lupin Europe (Knutsford)
|
9 | Mylan (Hatfield)
|
10 | Teva (Castleford)
|
Award Criteria
Logistics | 5.0 |
PRICE | 95.0 |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Award on basis of price and quality.
Other Information
The estimated value(s) referred to in Section II.1.5) and within all Lots cover(s) the fourteen (14) month contract duration and the twenty four (24)-month extension period of the framework agreement. (SC Ref:641923)
Reference
- OJEU 054126-2021